Skip to main content

Advertisement

Table 3 Prevention of breast events.

From: Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review

Outcome Studies Participants Risk Ratio (M-H, Fixed, 95% CI), I2
Tamoxifen (10 or 20 mg daily) versus no therapy/placebo    
Prevention of gynecomastia    
   • at 3 months Fradet 2007 94 0.06 (0.01, 0.43), -
   • at 6 months Fradet 2007, Perdona 2005 195 0.10 (0.05, 0.22), 0%
   • at 9 to 12 months Boccardo 2005, Fradet 2007 171 0.17 (0.09, 0.31), 0%
Prevention of breast pain    
   • at 3 months Fradet 2007, Saltzstein 2005 165 0.09 (0.03, 0.24), 74%a
   • at 6 months Fradet 2006, Perdona 2005 195 0.06 (0.02, 0.17), 27%
   • at 9 to 12 months Boccardo 2005, Fradet 2007 171 0.13 (0.06, 0.27), 0%
Tamoxifen (20 mg daily) versus anastrozole (1 mg daily)    
Prevention of gynecomastia    
   • median 12 months Boccardo 2005 73 0.22 (0.08, 0.58), -
Prevention of breast pain    
   • median 12 months Boccardo 2005, Saltzstein 2005 143 0.25 (0.10, 0.64), 0%
Tamoxifen (10 mg daily) versus radiotherapy    
Prevention of gynecomastia    
   • at 6 months Perdona 2005 100 0.24 (0.09, 0.65), -
Prevention of breast pain    
   • at 6 months Perdona 2005 100 0.20 (0.06, 0.65), -
  1. aRisk ratio with random effects model (M-H, 95% CI) 0.10 (0.01 to 0.90).